Funding for this research was provided by:
New National Natural Science Foundation of China (82172856)
New National Natural Science Foundation of China (81972805)
China National Major Project for New Drug Innovation (2017ZX09304015)
Received: 12 July 2022
Accepted: 31 October 2022
First Online: 23 November 2022
: The study was approved by the Ethics Committee of the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Permission No.15-139/1066); the Ethics Committee of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (Permission No.HS2017007); and the Ethics Committee of Tianjin Medical University Cancer Institute & Hospital (Permission No.E2018101) and conducted according to the Declaration of Helsinki, Guidelines for Good Clinical Practice, and local laws and regulations. All patients provided written informed consent.
: Not applicable.
: Yinghui Sun is an employee of Shouyao Holdings (Beijing) Co., Ltd, Beijing, China. The remaining authors declare no competing interests.